Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention? A Pre-Specified Analysis from the ZEUS Trial

JACC: Cardiovascular Interventions

Volumn 9, Issue 5, 2016, Pages 426-436

  Ariotti, Sara ^a,b   Adamo, Marianna ^b   Costa, Francesco ^b   Patialiakas, Athanasios ^c   Briguori, Carlo ^d   Thury, Attila ^e   Colangelo, Salvatore ^f   Campo, Gianluca ^g   Tebaldi, Matteo ^g   Ungi, Imre ^e   Tondi, Stefano ^h   Roffi, Marco ⁱ   Menozzi, Alberto ^j   De Cesare, Nicoletta ^k   Garbo, Roberto ^f   Meliga, Emanuele ^l   Testa, Luca ^m   Gabriel, Henrique Mesquita ⁿ   Ferlini, Marco ^o   Vranckx, Pascal ^p   Valgimigli, Marco ^a,b   more..

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Crete Naval Hospital   (Greece)

^d Clinica Mediterranea   (Italy)

^e Cardiology Center   (Hungary)

^f MOLINETTE HOSPITAL   (Italy)

^g UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^h District of Vignola   (Italy)

ⁱ UNIVERSITY HOSPITAL   (Switzerland)

^j UNIVERSITY HOSPITAL OF PARMA   (Italy)

^k Policlinico S Marco   (Italy)

^l MAURIZIANO HOSPITAL   (Italy)

^m IRCCS   (Italy)

ⁿ HOSPITAL DE SANTA CRUZ   (Portugal)

^o FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^p VIRGA JESSE HOSPITAL   (Belgium)

more..

Author keywords

dual antiplatelet therapy; high bleeding risk; zotarolimus eluting stent(s)

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; METAL; RAPAMYCIN; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; AGE; AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEATH; DEVICE SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; IMPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; ZOTAROLIMUS ELUTING CORONARY STENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DEVICES; DIAGNOSTIC IMAGING; DRUG ELUTING STENT; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PATIENT SELECTION; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SINGLE BLIND PROCEDURE; STENT; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; MALE; METALS; MYOCARDIAL INFARCTION; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SINGLE-BLIND METHOD; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84959863935     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.11.015     Document Type: Article

References (27)

1. M.C. Morice, P.W. Serruys, J.E. Sousa, et al. RAVEL Study Group A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
2. S.G. Ellis, D.A. Cox, J. Hermiller, et al. for the TAXUS-IV Investigators A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
3. M. Valgimigli, G. Campo, G. Percoco, et al. Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial JAMA 299 2008 1788 1799
4. M. Valgimigli, M. Tebaldi, M. Borghesi, et al. for the PRODIGY Investigators Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: A pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY) J Am Coll Cardiol Intv 7 2014 20 28
5. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern Circulation 115 2007 1440 1455
6. S. Windecker, P. Kolh, F. Alfonso, and et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 35 2014 2541 2619
7. G.N. Levine, E.R. Bates, J.C. Blankenship, and et al. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 122
8. D.E. Kandzari, M.B. Leon, J.J. Popma, et al. for the ENDEAVOR III Investigators Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial J Am Coll Cardiol 48 2006 2440 2447
9. M. Nishinari, T. Shimohama, T. Tojo, and et al. Two-week interval optical coherence tomography: Imaging evidence on neointimal coverage completion after implantation of the Endeavor zotarolimus-eluting stent Catheter Cardiovasc Interv 82 2013 E871 E878
10. M. Valgimigli, A. Patialiakas, A. Thury, and et al. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study Am Heart J 166 2013 831 838
11. M. Valgimigli, A. Patialiakas, A. Thury, et al. for the ZEUS Investigators Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates J Am Coll Cardiol 65 2015 805 815
12. S. Subherwal, R.G. Bach, A.Y. Chen, and et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score Circulation 119 2009 1873 1882
13. R. Mehran, S.J. Pocock, E. Nikolsky, and et al. A risk score to predict bleeding in patients with acute coronary syndromes J Am Coll Cardiol 55 2010 2556 2566
14. G.Y. Lip, L. Frison, J.L. Halperin, and D.A. Lane Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J Am Coll Cardiol 57 2011 173 180
15. S.D. Wiviott, E. Braunwald, C.H. McCabe, and et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
16. E. Camenzind, W. Wijns, L. Mauri, and et al. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation Am Heart J 158 2009 902 909.e5
17. J.W. Moses, M.B. Leon, J.J. Popma, and et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
18. M. Valgimigli, F. Costa, R. Byrne, and et al. Dual antiplatelet therapy duration after coronary stenting in clinical practice: Results of an EAPCI survey EuroIntervention 11 2015 68 74
19. M. Sabate, A. Cequier, A. Iñiguez, and et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1-year results of a randomised controlled trial Lancet 380 2012 1482 1490
20. L. Räber, H. Kelbæk, M. Ostojic, and et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: The COMFORTABLE AMI randomized trial JAMA 308 2012 777 787
21. L. Mauri, D.J. Kereiakes, R.W. Yeh, and et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents Engl J Med 371 2014 2155 2166
22. W.J. Dewilde, T. Oirbans, F.W. Verheugt, and et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial Lancet 381 2013 1107 1115
23. K.A. Fiedler, R.A. Byrne, S. Schulz, and et al. Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study Am Heart J 167 2014 459 465
24. G. Campo, M. Tebaldi, P. Vranckx, and et al. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: A PRODIGY trial substudy J Am Coll Cardiol 63 2014 506 512
25. M. Valgimigli, M. Sabaté, C. Kaiser, and et al. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: Patient level meta-analysis BMJ 349 2014 g6427
26. T. Palmerini, D. Sangiorgi, M. Valgimigli, and et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: An individual patient data pairwise and network meta-analysis J Am Coll Cardiol 65 2015 1092 1102
27. P. Urban, I.T. Meredith, A. Abizaid, and et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk N Engl J Med 373 2015 2038 2047